Navigation Links
Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Oncology
Date:11/18/2009

e further enhanced by the fact that Biothionol is already available for a different indication. We therefore expect an accelerated regulatory path to proof of clinical concept," said Guy Malchi, head of corporate development for Champions.

This is the third compound to be in-licensed into Champions' rapidly growing pipeline of oncology compounds. Recently, Champions announced the licensing of TAR-1, a single-chain antibody fragment, from Ramot at Tel Aviv University.

"We are excited to work with Champions' experienced scientific team to translate these promising early findings towards a meaningful clinical program by leveraging Champions' preclinical platform," said Demetrios Braddock, M.D., Ph.D., Associate Professor of Pathology in Yale School of Medicine and the Yale inventor of the licensed technology.

"It is gratifying to see the work of Southern Research and Yale scientists being channeled in this way, and to hopefully lead to the development of another new drug for cancer patients," said Nancy M. Gray, Ph.D., vice president of Corporate Development for Southern Research Institute. "This licensing opportunity with the Champions team fits quite well within Southern Research's own mission of conducting basic and translational research that ultimately leads to the approval of a new drug."

The work was funded, in part, by the Yale Clinical and Translational Science Award (CTSA) grant from the National Center for Research Resources at the National Institutes of Health.

About Champions Biotechnology, Inc.

Champions Biotechnology, Inc. is engaged in the development of advanced preclinical platforms and tumor specific data to enhance and accelerate the value of oncology drugs. The Company's Preclinical Platform is a novel approach based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments (Biomerk Tumorgrafts(TM))
'/>"/>

SOURCE Champions Biotechnology, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Champions Biotechnology to Present Data at AACR-EORTC 2009 Regarding the Predictability of Biomerk Tumorgraft(TM) Platform to Guide Personalized Cancer Treatment and Accelerate Oncology Drug Development
2. Champions Biotechnology Expands Collaboration to Test Oncology Therapeutic in Biomerk Tumorgrafts(TM)
3. Champions Biotechnology Reports Fiscal 2010 First Quarter Financial Results
4. Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement
5. Champions Biotechnology to Present at Rodman & Renshaws Eleventh Annual Healthcare Conference
6. Champions Biotechnology to Deploy its Technology to Guide Development of Oncology Therapeutic for Global Biotech Leader
7. Champions Biotechnology Reports Fiscal 2009 Full-Year Financial Results
8. Champions Biotechnology Partners with Do-Coop Technologies to Advance Its Novel Oncology Compound Into Biomerk Tumorgraft(TM) Testing
9. Champions Biotechnology, Inc. Establishes UK Subsidiary and Retains General Manager to Expand Its Personalized Oncology Business
10. Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results
11. Champions Biotechnology Reports Fiscal 2008 Full-Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... (PRWEB) January 14, 2014 Carahsoft and ... Thursday, January 23, 2014 at 2pm EST (11am PST), ... The topic focuses on how technology can turn raw, ... decisions for government agencies. The online webinar will last ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, has ... an emerging biomedical company acquiring, developing, manufacturing, and marketing ... Free report download: http://equitiesiq.com/reports/alliqua/ , In late ... and Board, which launched the company’s new strategy to ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 In recent ... motives and methods in product development and promotion has ... industry. This mistrust, fueled by concerns about the insidious ... by reports of spectacular fines to the world’s biggest ...
(Date:1/14/2014)... 13, 2014 Bob Hainsey, a semiconductor ... 20 years in the industry, has joined SPIE, ... will serve as the society’s Science and Technology Strategist. ... SPIE as our Technology Strategist, further strengthening the technical ...
Breaking Biology Technology:Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... Aoxing Pharmaceutical,Company, Inc. (OTC Bulletin Board: CAXG), which ... highly regulated narcotic,medicines and pain medication in China, ... fiscal 2008 ended September 30, 2007. China ... first quarter of fiscal 2008, a 33% sequential ...
... Convergence and New Opportunities, NEW BRUNSWICK, N.J., Nov. ... organizational changes to sharpen its,focus on opportunities outside its ... health care. These include the creation of a new,strategy ... The,changes are designed to accelerate growth for Johnson & ...
... 14 Advanced Life Sciences,Holdings, Inc. (Nasdaq: ... development and commercialization of novel drugs in the,therapeutic ... its financial results for the third quarter ended ... The net loss for the three months ended ...
Cached Biology Technology:China Aoxing Pharmaceutical Reports Financial Results for the First Quarter of Fiscal 2008 2China Aoxing Pharmaceutical Reports Financial Results for the First Quarter of Fiscal 2008 3China Aoxing Pharmaceutical Reports Financial Results for the First Quarter of Fiscal 2008 4China Aoxing Pharmaceutical Reports Financial Results for the First Quarter of Fiscal 2008 5Johnson & Johnson Announces Changes to Accelerate Growth 2Johnson & Johnson Announces Changes to Accelerate Growth 3Advanced Life Sciences Announces Third Quarter 2007 Financial Results 2Advanced Life Sciences Announces Third Quarter 2007 Financial Results 3Advanced Life Sciences Announces Third Quarter 2007 Financial Results 4Advanced Life Sciences Announces Third Quarter 2007 Financial Results 5Advanced Life Sciences Announces Third Quarter 2007 Financial Results 6Advanced Life Sciences Announces Third Quarter 2007 Financial Results 7Advanced Life Sciences Announces Third Quarter 2007 Financial Results 8Advanced Life Sciences Announces Third Quarter 2007 Financial Results 9
(Date:4/18/2014)... Peru found that 28 percent of the batches ... Many pills released the active ingredient too slowly. ... had no active ingredient at all. , ... Georgia Institute of Technology developed a sophisticated approach ... drugs and then characterize their chemical composition. The ...
(Date:4/18/2014)... URBANA, Ill. For the past 20 years, researchers ... of the research findings have suggested that soil organic ... or conventional tillage systems to no-till systems. However, there ... no-till systems in corn and soybean rotations without cover ... soil organic carbon stocks at the published rates. , ...
(Date:4/18/2014)... Asteroid and comet impacts can cause widespread ecological ... even global scales. But new research from Brown University ... ancient life at the time of an impact. , ... has found fragments of leaves and preserved organic compounds ... in Argentina. The material could provide a snapshot of ...
Breaking Biology News(10 mins):Counterfeit contraceptives found in South America 2Counterfeit contraceptives found in South America 3Researchers question published no-till soil organic carbon sequestration rates 2Researchers question published no-till soil organic carbon sequestration rates 3Researchers question published no-till soil organic carbon sequestration rates 4Impact glass stores biodata for millions of years 2Impact glass stores biodata for millions of years 3
... Cincinnati, OH, April 14, 2011 -- The number of couples ... often use assisted reproductive technologies, like in vitro fertilization (IVF), ... can also increase the risk of multiple pregnancies (i.e., twins ... one embryo. Twins and triplets are likely to be ...
... hormone known to inhibit aging can also protect kidneys against ... Scientists led by Dr. Makoto Kuro-o, associate professor of pathology, ... renal fibrosis a common complication of chronic kidney disease ... online in the Journal of Biological Chemistry . ...
... and economic security concerns have triggered interest in using algae-derived ... or any other biofuel source can require a ... smart about where we grow algae can drastically reduce how ... biofuel, while being water-wise, could also help meet congressionally mandated ...
Cached Biology News:New study finds stronger regulations of in vitro fertilization may save lives 2Anti-aging hormone Klotho inhibits renal fibrosis, cancer growth 2Study: Algae could replace 17 percent of US oil imports 2Study: Algae could replace 17 percent of US oil imports 3Study: Algae could replace 17 percent of US oil imports 4
...
... Signet offers the most comprehensive, cost-effective ... We have incorporated unprecedented quality into ... This includes proven detection chemistries and ... the TechMate protocol. It also includes ...
... Signets Xylene Resistant (X/R) Red System ... X/R Red Activator and X/R Red ... with alkaline phosphatase to produce red ... ,Kit Contains:, , Buffer, 100 ...
Human Cell Line Slides...
Biology Products: